ISPOR - RWD23 Comparison of the Use of Real-World Evidence (RWE) by Health Technology Assessment (HTA) Agencies in Reviews of Drugs for Rare Diseases (DRDS)

RWD23 Comparison of the Use of Real-World Evidence (RWE) by Health Technology Assessment (HTA) Agencies in Reviews of Drugs for Rare Diseases (DRDS)

Abstract

Authors

J. Kirby N. Tadros S. Gosain

Full Text Cite This Article

Back to Volume 26, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now